A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
Hosted on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback